Gunderson Dettmer Advises Vir Biotechnology on Underwritten Public Offering

Gunderson Dettmer represented Vir Biotechnology in its underwritten public offering of 20,294,117 shares of common stock at $8.50 per share, including the exercise in full of the underwriters’ option to purchase additional shares. 

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. 

The gross proceeds from the offering are expected to be $172.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. Vir Biotechnology sold all of the shares in the offering, which closed on February 27, 2026. 

The Gunderson deal team was led by Public Companies/Public Offerings partners Jeff Vetter and Alexa Belonick and included Public Companies/Public Offerings associates Daniel Reichert, Michael Tiab, and Lydia Wang, tax partner Jace Clegg, and senior paralegal Scott Paraker.